Alliance for Clinical Trials in Oncology
allianceforclinicaltrialsinoncology.orgTotal trials
508
Active
70
Phase 3
160
Total enrollment
177,735
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 111 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| oxaliplatin | — | — | 25 | ||||
| Pembrolizumab | — | — | — | — | 5 | ||
| carboplatin | — | — | — | 42 | |||
| cisplatin | — | — | — | 26 | |||
| leucovorin calcium | — | — | — | — | 24 | ||
| Nivolumab | — | — | — | — | 4 | ||
| fluorouracil | — | — | — | 24 | |||
| docetaxel | — | — | — | — | 25 | ||
| rituximab | — | — | — | 23 | |||
| dexamethasone | — | — | — | — | 15 | ||
| cytarabine | — | — | — | — | 14 | ||
| temozolomide | — | — | — | — | 9 | ||
| Irinotecan | — | — | — | 7 | |||
| Gemcitabine | — | — | — | — | 4 | ||
| Enzalutamide | — | — | — | — | 4 | ||
| irinotecan hydrochloride | — | — | — | 26 | |||
| methotrexate | — | — | — | — | 17 | ||
| cetuximab | — | — | — | — | 11 | ||
| Vincristine | — | — | — | — | 4 | ||
| Mercaptopurine | — | — | — | — | 4 | ||
| Doxorubicin | — | — | — | — | 4 | ||
| G-CSF | — | — | — | — | 4 | ||
| Pemetrexed | — | — | — | — | 3 | ||
| Lutetium Lu 177 Vipivotide Tetraxetan | — | — | — | — | 2 | ||
| Inotuzumab Ozogamicin | — | — | — | — | 2 | ||
| Avelumab | — | — | — | — | 2 | ||
| Zanubrutinib | — | — | — | — | — | 2 | |
| Atezolizumab | — | — | — | — | — | 2 | |
| cyclophosphamide | — | — | 23 | ||||
| chemotherapy | — | — | — | 7 | |||
| bevacizumab | — | — | — | — | 20 | ||
| vincristine sulfate | — | — | — | 12 | |||
| gabapentin | — | — | — | — | — | 5 | |
| trastuzumab | — | — | — | — | 5 | ||
| fulvestrant | — | — | — | — | 4 | ||
| ifosfamide | — | — | — | — | 4 | ||
| mycophenolate mofetil | — | — | — | — | 4 | ||
| Allopurinol | — | — | — | — | 4 | ||
| Olanzapine | — | — | — | — | — | 3 | |
| daunorubicin hydrochloride | — | — | — | — | 3 |
71 more active programs hidden
Next readouts
- 2018-10-02
- 2019-02-21
- 2020-12-10
- 2021-01-28
- 2023-10-31
- 2023-11-10
- 2024-06-01
- 2024-07-15
- 2025-02-26
- 2025-11-26
Top conditions
- Lung Cancer78
- Breast Cancer72
- Lymphoma45
- Colorectal Cancer41
- Leukemia40
- Unspecified Adult Solid Tumor, Protocol Specific34
- Prostate Cancer29
- Esophageal Cancer19
Frequently asked questions about Alliance for Clinical Trials in Oncology
- How many clinical trials does Alliance for Clinical Trials in Oncology have on ClinicalTrials.gov?
- Alliance for Clinical Trials in Oncology is listed as the lead sponsor on 508 clinical trials in ClinicalTrials.gov, 70 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Alliance for Clinical Trials in Oncology's trials are in Phase 3?
- 160 of Alliance for Clinical Trials in Oncology's trials are in Phase 3, spread across 111 active drug programs.
- What therapeutic areas does Alliance for Clinical Trials in Oncology focus on?
- Alliance for Clinical Trials in Oncology's most-studied conditions on ClinicalTrials.gov are Lung Cancer, Breast Cancer, Lymphoma, Colorectal Cancer, Leukemia.
- When are Alliance for Clinical Trials in Oncology's next clinical trial readouts?
- Alliance for Clinical Trials in Oncology has 10 upcoming primary-completion readouts tracked here; the soonest is “Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer”, expected around 2018-10-02.